In our second episode of the “Immuno Oncology Talks”, Associate Professor Evren Alici, from the Karolinska Institutet in Sweden, was invited to discuss NK cell-based cancer immunotherapies, accompanied by his colleague Professor Hans-Gustaf Ljunggren. The primary focus of Professor Alici´s research is on novel NK cell-based therapies, and includes generation and testing of genetically engineered NK cells, like chimeric receptor and CAR-NK cells. Associate Professor Alici is also co-director of the NextGenNK Competence Center (https://ki.se/en/research/nextgennk).
MAT-BE-2200747 (ver 1.0) 09 2022
In our second episode of the “Immuno Oncology Talks”, Associate Professor Evren Alici, from the Karolinska Institutet in Sweden, was invited to discuss NK cell-based cancer immunotherapies, accompanied by his colleague Professor Hans-Gustaf Ljunggren. The primary focus of Professor Alici´s research is on novel NK cell-based therapies, and includes generation and testing of genetically engineered NK cells, like chimeric receptor and CAR-NK cells. Associate Professor Alici is also co-director of the NextGenNK Competence Center (https://ki.se/en/research/nextgennk).
MAT-BE-2200747 (ver 1.0) 09 2022